Oncogene Cancer Research shared on LinkedIn:
“Lung cancer screening still leans heavily on smoking history, and that leaves people out.
A new study by Ibukunoluwapo Zabroski, Daniel Salem and colleagues at Mercy BioAnalytics, Inc., published in Scientific Reports, tests a blood-based alternative: a test that looks for tumour-derived particles rather than relying on scans or smoking history alone.
- It caught 100% of stage III/IV cases and 83% of stage II cases (at 90% specificity)
- Stage I detection was lower, around 49%, showing how much harder very early disease still is to catch
- Crucially, the test’s signal tracked with tumour size, not with smoking history
It’s a small, early feasibility study, not yet a validated clinical test. But screening that follows the biology, not a person’s history, is exactly what we need if we’re serious about catching lung cancer early in everyone.”
Title: Detection of early-stage lung adenocarcinoma using a novel extracellular vesicle and particle-based blood test
Authors: Ibukunoluwapo O. Zabroski, Daniel P. Salem, Aaron Chevalier, Timothy Santos-Heiman, Nina A. Insixiengmay, Brittany Grimes, Katherine S. Yang, Gabrielle N. Barcaskey, MacKenzie S. King, Syrena C. Fernandes, Troy B. Hawkins, Michael J. Smith, Brendan J. Manning, Dawn R. Mattoon, Toumy Guettouche
Other articles about Lung cancer on OncoDaily.